Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Potential Colon Cancer Biomarker Revealed

By Drug Discovery Trends Editor | January 16, 2009

Cincinnati scientists have identified a new biomarker that could help predict a person’s risk of developing colon cancer and how aggressive it may become.
 
The University of Cincinnati (UC) team has identified hotspots—areas of deleted genetic data—that play a critical role in regulating gene expression and influence colon cancer progression. Researchers speculate that these hotspots could be used as a biomarker for colon cancer.
 
This study is the first to explain how a gene—AMACR—is regulated in relation to cancer development and to identify specific genetic events (a polymorphism and somatic cell mutations) related to colon cancer.
 
For this study, UC researchers looked at the actions of the AMACR gene in human tissue. AMACR breaks down branched-chain fatty acids, a type of molecule only found in animals that eat plants. Previous research showed that plant-derived fatty acids, such as those found in red meat and dairy products, can accelerate cancer growth.
 
‘From the colon tissues, we’ve identified two types of genetic deletions that may allow us to predict whether people will have a good or bad cancer outcome,’ says Xiang Zhang, PhD, first author of the study and UC environmental health research associate. ‘If a person carries one of the deletions, it may predispose him or her to a more aggressive type of colon cancer.’
 
UC researchers analyzed the AMACR gene’s abnormal expression patterns using a sophisticated laser-capture microdissection technique to identify the key biological events that lead to colon cancer progression. They also compared gene sequencing data from the general population—obtained from whole blood samples—to that of the human colon cancer tissue samples.
 
In addition to discovering the hotspots that trigger abnormal AMACR expression, they also identified specific proteins (transcription factors) that would normally bind to the deleted sequences to maintain normal gene expression.
 
‘Our hope is that this new knowledge will help us develop better diagnostic tools for colon cancer,’ says Zhang.
 
Researchers say this discovery could also help people make strategic lifestyle choices to reduce their risk for developing colon and other cancers from a gene-environmental interaction.
 
‘For years, scientists have believed that a diet including a large amount of red meat and low in fiber may lead to increased risk for colon cancer, but it’s not that linear,’ says Shuk-mei Ho, PhD, senior author of the study and chair of UC’s environmental health department. ‘We need to start paying closer attention to how the environment we live in and the things we put in our bodies interact with our genetic makeup to influence our cancer risk.”’
 
The UC research team expects to expand this research into a multi-center study in the near future.

Release Date: January 15, 2009
Source: University of Cincinnati


Filed Under: Genomics/Proteomics

 

Related Articles Read More >

Columbia-CZ team develops 10.3M parameter model that outperforms 100M parameter rivals on cell type classification
Spatial biology: Transforming our understanding of cellular environments
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
DNA helix 3D illustration. Mutations under microscope. Decoding genome. Virtual modeling of chemical processes. Hi-tech in medicine
Genomics in 2025: How $500 whole genome sequencing could democratize genomic data
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2026 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE